Loading...

AirXpanders

ASX:AXP
Snowflake Description

Limited growth with imperfect balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
AXP
ASX
A$20M
Market Cap
  1. Home
  2. AU
  3. Healthcare
Company description

AirXpanders, Inc., a medical device company, designs, manufactures, sells, and distributes medical devices in the Australia, the United States, and Europe. The last earnings update was 57 days ago. More info.


Add to Portfolio Compare Print
AXP Share Price and Events
7 Day Returns
0%
ASX:AXP
2.3%
AU Medical Equipment
1.8%
AU Market
1 Year Returns
-75%
ASX:AXP
-1.1%
AU Medical Equipment
6%
AU Market
AXP Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
AirXpanders (AXP) 0% 2.9% 9.4% -75% -96% -
AU Medical Equipment 2.3% 4% -0.1% -1.1% 44.3% 109.3%
AU Market 1.8% 3.9% 7.8% 6% 20.5% 8.4%
1 Year Return vs Industry and Market
  • AXP underperformed the Medical Equipment industry which returned -1.1% over the past year.
  • AXP underperformed the Market in Australia which returned 6% over the past year.
Price Volatility
AXP
Industry
5yr Volatility vs Market

Value

 Is AirXpanders undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for AirXpanders. This is due to cash flow or dividend data being unavailable. The share price is A$0.035.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for AirXpanders's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are AirXpanders's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:AXP PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.07
ASX:AXP Share Price ** ASX (2019-03-28) in AUD A$0.04
ASX:AXP Share Price converted to USD reporting currency Exchange rate (AUD/ USD) 0.701 $0.02
Australia Medical Equipment Industry PE Ratio Median Figure of 8 Publicly-Listed Medical Equipment Companies 34.76x
Australia Market PE Ratio Median Figure of 543 Publicly-Listed Companies 16.33x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of AirXpanders.

ASX:AXP PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:AXP Share Price ÷ EPS (both in USD)

= 0.02 ÷ -0.07

-0.35x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • AirXpanders is loss making, we can't compare its value to the AU Medical Equipment industry average.
  • AirXpanders is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does AirXpanders's expected growth come at a high price?
Raw Data
ASX:AXP PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.35x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
Oceania Medical Equipment Industry PEG Ratio Median Figure of 5 Publicly-Listed Medical Equipment Companies 2.67x
Australia Market PEG Ratio Median Figure of 359 Publicly-Listed Companies 1.39x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for AirXpanders, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on AirXpanders's assets?
Raw Data
ASX:AXP PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.01
ASX:AXP Share Price * ASX (2019-03-28) in AUD A$0.04
ASX:AXP Share Price converted to USD reporting currency Exchange rate (AUD/ USD) 0.701 $0.02
Australia Medical Equipment Industry PB Ratio Median Figure of 30 Publicly-Listed Medical Equipment Companies 2.77x
Australia Market PB Ratio Median Figure of 1,676 Publicly-Listed Companies 1.67x
ASX:AXP PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:AXP Share Price ÷ Book Value per Share (both in USD)

= 0.02 ÷ 0.01

3.03x

* Primary Listing of AirXpanders.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • AirXpanders is overvalued based on assets compared to the AU Medical Equipment industry average.
X
Value checks
We assess AirXpanders's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. AirXpanders has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is AirXpanders expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
41.3%
Expected annual growth in revenue.
Earnings growth vs Low Risk Savings
Is AirXpanders expected to grow at an attractive rate?
  • Unable to compare AirXpanders's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare AirXpanders's earnings growth to the Australia market average as no estimate data is available.
  • AirXpanders's revenue growth is expected to exceed the Australia market average.
Annual Growth Rates Comparison
Raw Data
ASX:AXP Future Growth Rates Data Sources
Data Point Source Value (per year)
ASX:AXP Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 41.3%
Australia Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 13.1%
Australia Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 8.4%
Australia Market Earnings Growth Rate Market Cap Weighted Average 6.8%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:AXP Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:AXP Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 101 32 1
2022-12-31 75 15 1
2021-12-31 49 2 1
2020-12-31 29 -7 1
2019-12-31 15 -14 1
ASX:AXP Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 8 -26 -27
2018-09-30 8 -29 -29
2018-06-30 7 -34 -28
2018-03-31 5 -34 -28
2017-12-31 4 -32 -29
2017-09-30 2 -30 -27
2017-06-30 1 -25 -26
2017-03-31 1 -22 -23
2016-12-31 1 -19 -19
2016-09-30 0 -18 -17
2016-06-30 0 -16 -15
2016-03-31 0 -13 -13

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if AirXpanders is high growth as no earnings estimate data is available.
  • AirXpanders's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:AXP Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from AirXpanders Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:AXP Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31
ASX:AXP Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.07
2018-09-30 -0.09
2018-06-30 -0.10
2018-03-31 -0.10
2017-12-31 -0.10
2017-09-30 -0.10
2017-06-30 -0.10
2017-03-31 -0.10
2016-12-31 -0.09
2016-09-30 -0.07
2016-06-30 -0.06
2016-03-31 -0.06

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if AirXpanders will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess AirXpanders's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
AirXpanders has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has AirXpanders performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare AirXpanders's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • AirXpanders does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare AirXpanders's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare AirXpanders's 1-year growth to the AU Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
AirXpanders's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from AirXpanders Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:AXP Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 7.82 -26.72 15.41 4.29
2018-09-30 7.58 -29.09 16.07 5.90
2018-06-30 6.69 -27.69 15.87 6.97
2018-03-31 5.40 -28.13 14.89 8.12
2017-12-31 3.91 -28.98 14.39 8.73
2017-09-30 2.31 -26.67 12.60 8.36
2017-06-30 1.31 -25.90 11.45 8.22
2017-03-31 0.73 -22.82 9.78 7.92
2016-12-31 0.57 -19.42 7.99 7.16
2016-09-30 0.50 -17.35 7.63 6.09
2016-06-30 0.46 -15.41 7.06 5.23
2016-03-31 0.36 -12.76 5.68 4.68
2015-12-31 0.29 -11.16 4.64 4.83
2015-09-30 0.17 -9.67 3.61 4.93
2015-06-30 0.05 -8.19 2.58 5.03
2015-03-31 0.02 -7.58 2.40 4.59
2014-12-31 -6.98 2.23 4.14
2013-12-31 -6.07 1.99 3.89
2012-12-31 -6.64 1.90 4.60

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if AirXpanders has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if AirXpanders has efficiently used its assets last year compared to the AU Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if AirXpanders improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess AirXpanders's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
AirXpanders has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is AirXpanders's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up AirXpanders's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • AirXpanders is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • AirXpanders's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of AirXpanders's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from AirXpanders Company Filings, last reported 3 months ago.

ASX:AXP Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 4.53 14.91 9.38
2018-09-30 9.60 14.82 14.32
2018-06-30 3.24 14.83 6.46
2018-03-31 10.60 14.75 13.62
2017-12-31 16.84 14.62 22.59
2017-09-30 24.31 14.52 30.82
2017-06-30 29.88 0.51 27.15
2017-03-31 37.68 0.85 36.85
2016-12-31 12.17 1.20 11.48
2016-09-30
2016-06-30 22.54 1.93 23.34
2016-03-31 17.05 2.58 19.11
2015-12-31 17.05 2.58 19.11
2015-09-30 17.05 2.58 19.11
2015-06-30 23.45 3.32 27.93
2015-03-31 23.45 3.32 27.93
2014-12-31 -2.19 3.56 1.65
2013-12-31
2012-12-31
  • AirXpanders's level of debt (329.4%) compared to net worth is high (greater than 40%).
  • Unable to establish if AirXpanders's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • AirXpanders has less than a year of cash runway based on current free cash flow.
  • AirXpanders has less than a year of cash runway if free cash flow continues to grow at historical rates of 29.1% each year.
X
Financial health checks
We assess AirXpanders's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. AirXpanders has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is AirXpanders's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from AirXpanders dividends.
If you bought A$2,000 of AirXpanders shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate AirXpanders's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate AirXpanders's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:AXP Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Oceania Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 1.7%
Australia Market Average Dividend Yield Market Cap Weighted Average of 417 Stocks 4.3%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.5%
Australia Bottom 25% Dividend Yield 25th Percentile 2.5%
Australia Top 25% Dividend Yield 75th Percentile 5.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ASX:AXP Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as AirXpanders has not reported any payouts.
  • Unable to verify if AirXpanders's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of AirXpanders's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as AirXpanders has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess AirXpanders's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can AirXpanders afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. AirXpanders has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of AirXpanders's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Frank Grillo
AGE 56
TENURE AS CEO 0.8 years
CEO Bio

Mr. Frank P. Grillo, also known as Frank, has been the President, Chief Executive Officer and Executive Director of AirXpanders, Inc. since joining in June 12, 2018. Mr. Grillo has been an Executive Advisor of MRI Interventions, Inc. since November 7, 2017. Mr. Grillo served as the Chief Executive Officer of MRI Interventions, Inc. since January 1, 2015 until November 6, 2017 and President since October 06, 2014 until November 6, 2017. Mr. Grillo served as President MRI Interventions, Inc since October 6, 2014. Mr. Grillo served as Vice President of Marketing & Business Development at Intuitive Surgical, Inc., since November 2008. Mr. Grillo served as Vice President of Business Development for Intuitive Surgical, Inc. since August 2008 until November 2008. Before joining Intuitive Surgical, Mr. Grillo worked for Kyphon Inc. from February 2006 to June 2008. He served as Vice President of Strategy and Business Development for Medtronic Spine LLC since February 6, 2006. He served in various positions at Boston Scientific Corporation for ten years including Vice President of Marketing of Women's Health, Urology/Gynecology Division from May 2002 to January 2006 and Vice President of Marketing, New Modalities, Urology Division from March 2000 to April 2002. Prior to his role in Marketing, he served as Director of New Business Development for the cardiology and drug delivery groups at Boston Scientific for four years. He served as a Director of MRI Interventions, Inc. since April 1, 2015 until November 6, 2017. Mr. Grillo holds an MBA from the J.L. Kellogg Graduate School of Business at Northwestern University and a Bachelor of Science in Chemical Engineering from Tufts University.

CEO Compensation
  • Insufficient data for Frank to compare compensation growth.
  • Insufficient data for Frank to establish whether their remuneration is reasonable compared to companies of similar size in Australia.
Management Team Tenure

Average tenure and age of the AirXpanders management team in years:

1.2
Average Tenure
56
Average Age
  • The average tenure for the AirXpanders management team is less than 2 years, this suggests a new team.
Management Team

Barry Cheskin

TITLE
Co-Founder & Non-Executive Chairman of the Board
COMPENSATION
$106K
AGE
57

Scott Murcray

TITLE
CFO & COO
COMPENSATION
$303K
AGE
47
TENURE
2.8 yrs

Frank Grillo

TITLE
President
AGE
56
TENURE
0.8 yrs

Daniel Jacobs

TITLE
Co-Founder & Medical Adviser

Melissa Comunale

TITLE
Vice President of Sales
TENURE
1.3 yrs

Laurel Burk

TITLE
Director of Marketing
TENURE
1.1 yrs
Board of Directors Tenure

Average tenure and age of the AirXpanders board of directors in years:

3
Average Tenure
60.5
Average Age
  • The tenure for the AirXpanders board of directors is about average.
Board of Directors

Barry Cheskin

TITLE
Co-Founder & Non-Executive Chairman of the Board
COMPENSATION
$106K
AGE
57

Frank Grillo

TITLE
President
AGE
56
TENURE
0.8 yrs

Greg Lichtwardt

TITLE
Non-Executive Director
COMPENSATION
$57K
AGE
64
TENURE
3 yrs

Zita Peach

TITLE
Non-Executive Director
COMPENSATION
$59K
AGE
53
TENURE
3 yrs

Dennis Condon

TITLE
Non-Executive Director
COMPENSATION
$49K
AGE
69
TENURE
6.7 yrs

Liz Hammack

TITLE
Non-Executive Director
COMPENSATION
$50K
AGE
66
TENURE
1.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
30. Oct 18 Buy Barry Cheskin Individual 26. Oct 18 26. Oct 18 897,180 A$0.08 A$70,987
31. Aug 18 Buy Viburnum Funds Pty Ltd. Company 03. Aug 18 31. Aug 18 33,063,627 A$0.08 A$2,795,219
08. May 18 Buy Zita Peach Individual 07. May 18 07. May 18 83,333 A$0.17 A$14,115
X
Management checks
We assess AirXpanders's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. AirXpanders has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

AirXpanders, Inc. (ASX:AXP) Insiders Increased Their Holdings

So shareholders might well want to know whether insiders have been buying or selling shares in AirXpanders, Inc. … The Last 12 Months Of Insider Transactions At AirXpanders. … In the last twelve months there was more buying than selling by AirXpanders insiders

Simply Wall St -

Introducing AirXpanders, The Stock That Collapsed 97%

Indeed, the share price is down a whopping 97% in the last three years. … AirXpanders isn't yet profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. … Shareholders of unprofitable companies usually expect strong revenue growth

Simply Wall St -

Do Institutions Own Shares In AirXpanders, Inc. (ASX:AXP)?

(ASX:AXP), then you'll have to look at the makeup of its share registry. … Taking a look at the our data on the ownership groups (below), it's seems that. … Let's take a closer look to see what the different types of shareholder can tell us about AXP

Simply Wall St -

Is AirXpanders Inc's (ASX:AXP) Balance Sheet A Threat To Its Future?

Investors are always looking for growth in small-cap stocks like AirXpanders Inc (ASX:AXP), with a market cap of AU$25.04m. … However, an important fact which most ignore is: how financially healthy is the business? … Companies operating in the Medical Equipment industry,

Simply Wall St -

Should You Buy AirXpanders Inc (ASX:AXP) For This Reason?

The measure of how fast AirXpanders goes through its cash reserves over time is called the cash burn rate. … This means that, if AirXpanders continues to grow its opex at this rate, given how much money it currently has in the bank, it will actually need to raise capital again in within the next 8 months! … The cash burn analysis result indicates a cash constraint for the company, due to its high opex growth and its level of cash reserves.

Simply Wall St -

AirXpanders Inc (ASX:AXP): Risks You Need To Consider Before Buying

A widely-used metric to measure a stock's market risk is beta, and the broad market index represents a beta value of one. … Based on this beta value, AXP appears to be a stock that an investor with a high-beta portfolio would look for to reduce risk exposure to the market. … AXP, with its market capitalisation of AU$27.34M, is a small-cap stock, which generally have higher beta than similar companies of larger size.

Simply Wall St -

What does AirXpanders Inc's (ASX:AXP) Balance Sheet Tell Us About Its Future?

Moving onto cash from operations, its small level of operating cash flow means calculating cash-to-debt wouldn't be too useful, though these low levels of cash means that operational efficiency is worth a look. … Running high debt, while not yet making money, can be risky in unexpected downturns as liquidity may dry up, making it hard to operate.Next Steps: AXP’s debt and cash flow levels indicate room for improvement. … Its cash flow coverage of less than a quarter of debt means that operating efficiency could be an issue.

Simply Wall St -

Have You Considered This Before Investing In AirXpanders Inc (ASX:AXP)?

Free Cash Flow = Operating Cash Flows – Net Capital Expenditure Free Cash Flow Yield = Free Cash Flow / Enterprise Value where Enterprise Value = Market Capitalisation + Net Debt After accounting for capital expenses required to run the business, AirXpanders is not able to generate positive FCF, leading to a negative FCF yield – not very useful for interpretation! … Below is a table of AirXpanders’s operating cash flow in the past year, as well as the anticipated level going forward. … Current +1 year +2 year +3 year Operating Cash Flow (OCF) -US$32.45M -US$20.80M -US$13.40M US$1.26M OCF Growth Year-On-Year -35.91% -35.58% -109.40% OCF Growth From Current Year -58.71% -103.88% Next Steps: Now you know to keep cash flows in mind, I recommend you continue to research AirXpanders to get a better picture of the company by looking at: Historical Performance: What has AXP's returns been like over the past?

Simply Wall St -

Who Are The Major Shareholders Of AirXpanders Inc (ASX:AXP)?

In this article, I'm going to take a look at AirXpanders Inc’s (ASX:AXP) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors. … This size of ownership gives retail investors collective power in deciding on major policy decisions such as executive compensation, appointment of directors and acquisitions of businesses. … Thus, investors not need worry too much about the consequences of these holdings.Next Steps: With significant institutional ownership, including active hedge, existing investors should seek a margin of safety when investing in AXP.

Simply Wall St -

Why AirXpanders Inc (ASX:AXP) Could Be A Buy

ASX:AXP Future Profit Mar 17th 18 Future outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. … Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company's future expectations. … AXP’s optimistic future growth appears to have been factored into the current share price, with shares trading above its fair value.

Simply Wall St -

Company Info

Description

AirXpanders, Inc., a medical device company, designs, manufactures, sells, and distributes medical devices in the Australia, the United States, and Europe. The company's product, AeroForm Tissue Expander System, is a needle-free, patient-controlled tissue expander used for patients undergoing two-stage breast reconstruction following mastectomy prior to the insertion of a breast implant. AirXpanders, Inc. was founded in 2005 and is headquartered in San Jose, California.

Details
Name: AirXpanders, Inc.
AXP
Exchange: ASX
Founded: 2005
A$19,546,290
558,465,433
Website: http://www.airxpanders.com
Address: AirXpanders, Inc.
3047 Orchard Parkway,
San Jose,
California, 95134,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX AXP NPV CDI 1:3 Australian Securities Exchange AU AUD 22. Jun 2015
OTCPK ARXX.L NPV CDI 1:3 Pink Sheets LLC US USD 22. Jun 2015
DB A1W NPV CDI 1:3 Deutsche Boerse AG DE EUR 22. Jun 2015
Number of employees
Current staff
Staff numbers
70
AirXpanders employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/26 10:35
End of day share price update: 2019/03/28 00:00
Last estimates confirmation: 2019/02/28
Last earnings filing: 2019/02/28
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.